JATENZO® Oral Testosterone Undecanoate - Efficacy, Flexible dosing and Safety Profile

madman · Dec 25, 2025

madman · Dec 25, 2025

Thread 'Treatment of Symptomatic Male Hypogonadism with New Oral Testosterone Therapies: A Comparative Review of Jatenzo, Tlando, and Kyzatrex'

Dec 24, 2025

https://www.mdpi.com/2305-6320/13/1/1#

Abstract

Symptomatic male hypogonadism, defined by low serum testosterone with associated clinical symptoms, is increasingly treated with testosterone replacement therapy. Traditional oral formulations were limited by hepatotoxicity and poor bioavailability, leading to reliance on injectable and transdermal routes. Recent advances in oral testosterone undecanoate formulations have introduced safer and more effective options. This review compares Jatenzo, Tlando, and Kyzatrex, highlighting their pharmacology, efficacy, safety, and...

madman · Dec 25, 2025

Thread 'Oral T Dosing and Lab Strategies'

Dec 25, 2025

madman · Jan 3, 2026

Thread 'Oral TU Formulations (Andriol®, JATENZO®,TLANDO®, KYZATREX® for T Therapy'

Jan 3, 2026

* Oral TRT, particularly testosterone undecanoate (TU), offers notable convenience. TU is absorbed via the lymphatic system, bypassing first-pass hepatic metabolism, making it a promising agent for TRT. Its absorption, however, is influenced by dietary factors, such as lipid intake, thus the high-fat consumption promoting lymphatic absorption. Pharmaceutical technology developed TU formulations incorporate special self-emulsifying systems that enhance lymphatic absorption regardless of food fat content. This lymphatic absorption allows for stable testosterone levels...

madman · 2026-02-12T17:29:58-0600

Thread 'Oral Testosterone Therapy: Is It Really Safe?'

Today at 5:28 PM

* newer generation of oral testosterone therapy is forcing the medical world to update outdated talking points

What if everything you thought you knew about testosterone therapy was wrong? For decades, we’ve been told oral testosterone is dangerous—hard on the liver, risky for the heart, and “not worth it.”

In this episode, I sit down with Shalin Shah, CEO of Marius Pharmaceuticals, to unpack what’s changed and why a newer generation of oral testosterone therapy is forcing the medical world to update outdated talking points...